Abstract: Ｏｂｊｅｃｔｉｖｅ：To investigate the effect of Roxadustat on anemia in maintenance hemodialysis (MHD) patients with different iron metabolism status.
Ｍｅｔｈｏｄｏｌｏｇｙ：A prospective study, 96 MHD patients with renal anemia from 10 dialysis centers in Sichuan Province were selected. According to the baseline serum ferritin (SF) level, the patients were divided into normal SF group (SF≤500 ng／L) and iron overload group (SF>500 ng／L). All subjects were treated with Roxadustat for 12 weeks according to their body weight. Hemoglobin (Hb), iron metabolism indexes ［SF, transferrin saturation (TSAT), total iron binding capacity (TIBC)］ were detected before and after treatment, and adverse reactions were monitored during treatment.
Ｒｅｓｕｌｔｓ：Hb in normal SF and iron overload group increased significantly compared with that before treatment(P<0001), and there was no significant difference in Hb changes between the two groups(P=0897). After treatment, SF decreased and TIBC increased in both groups, and the difference was statistically significant; however, SF decreased greatly and TIBC increased slightly in iron overload group. TSAT remained stable in both groups. No severe adverse reactions were found during the treatment.
Ｃｏｎｃｌｕｓｉｏｎ：Roxadustat can effectively correct anemia and improve iron metabolism in different iron metabolism states, but there are different improvement degrees for iron metabolism.